Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Congenital antithrombin deficiency type 3


Other Names for this Disease
  • Antithrombin III Deficiency
  • Congenital Antithrombin III Deficiency
  • Congenital AT-III deficiency
  • Thrombophilia due to antithrombin III deficiency
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment


Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Congenital antithrombin deficiency type 3. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Antithrombin III (human)
Trade Name
(Manufacturer Name)
ATnativ
(Pharmacia & Upjohn AB)
Indication
The FDA has approved this product to be used in this manner.
For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.
More Information about this product Drug Information Portal

Generic Name Recombinant human antithrombin
Trade Name
(Manufacturer Name)
Atryn®
(GTC Biotherapeutics, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.
More Information about this product Drug Information Portal

Generic Name Antithrombin III (human)
Trade Name
(Manufacturer Name)
Thrombate III®
(Talecris Biotherapeutics)
Indication
The FDA has approved this product to be used in this manner.
For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.
More Information about this product Drug Information Portal